Tags

Type your tag names separated by a space and hit enter

Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis.
J Fam Pract. 2002 May; 51(5):425-30.JF

Abstract

OBJECTIVE

We assessed the efficacy of S-adenosylmethionine (SAMe), a dietary supplement now available in the Unites States, compared with that of placebo or nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA).

STUDY DESIGN

This was a meta-analysis of randomized controlled trials.

DATA SOURCES

We identified randomized controlled trials of SAMe versus placebo or NSAIDS for the treatment of OA through computerized database searches and reference lists.

OUTCOMES MEASURED

The outcomes considered were pain, functional limitation, and adverse effects.

RESULTS

Eleven studies that met the inclusion criteria were weighted on the basis of precision and were combined for each outcome variable. When compared with placebo, SAMe is more effective in reducing functional limitation in patients with OA (effect size [ES] =.31; 95% confidence interval [CI],.099-.520), but not in reducing pain (ES =.22; 95% CI, -.247 to.693). This result, however, is based on only 2 studies. SAMe seems to be comparable with NSAIDs (pain: ES =.12; 95% CI, -.029 to.273; functional limitation: ES =.025; 95% CI, -.127 to.176). However, those treated with SAMe were less likely to report adverse effects than those receiving NSAIDs.

CONCLUSIONS

SAMe appears to be as effective as NSAIDs in reducing pain and improving functional limitation in patients with OA without the adverse effects often associated with NSAID therapies.

Authors+Show Affiliations

Soeken KL
University of Maryland, School of Nursing, Baltimore, MD, USA. ksoeken@compmed.umm.edu
Lee WL
No affiliation info available
Bausell RB
No affiliation info available
Agelli M
No affiliation info available
Berman BM
No affiliation info available

MeSH

Anti-Inflammatory Agents, Non-SteroidalComplementary TherapiesDietary SupplementsHumansOsteoarthritisRandomized Controlled Trials as TopicS-Adenosylmethionine

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

12019049

Citation

Soeken, Karen L., et al. "Safety and Efficacy of S-adenosylmethionine (SAMe) for Osteoarthritis." The Journal of Family Practice, vol. 51, no. 5, 2002, pp. 425-30.
Soeken KL, Lee WL, Bausell RB, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. 2002;51(5):425-30.
Soeken, K. L., Lee, W. L., Bausell, R. B., Agelli, M., & Berman, B. M. (2002). Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. The Journal of Family Practice, 51(5), 425-30.
Soeken KL, et al. Safety and Efficacy of S-adenosylmethionine (SAMe) for Osteoarthritis. J Fam Pract. 2002;51(5):425-30. PubMed PMID: 12019049.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. AU - Soeken,Karen L, AU - Lee,Wen-Lin, AU - Bausell,R Barker, AU - Agelli,Maria, AU - Berman,Brian M, PY - 2002/5/23/pubmed PY - 2002/6/6/medline PY - 2002/5/23/entrez SP - 425 EP - 30 JF - The Journal of family practice JO - J Fam Pract VL - 51 IS - 5 N2 - OBJECTIVE: We assessed the efficacy of S-adenosylmethionine (SAMe), a dietary supplement now available in the Unites States, compared with that of placebo or nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA). STUDY DESIGN: This was a meta-analysis of randomized controlled trials. DATA SOURCES: We identified randomized controlled trials of SAMe versus placebo or NSAIDS for the treatment of OA through computerized database searches and reference lists. OUTCOMES MEASURED: The outcomes considered were pain, functional limitation, and adverse effects. RESULTS: Eleven studies that met the inclusion criteria were weighted on the basis of precision and were combined for each outcome variable. When compared with placebo, SAMe is more effective in reducing functional limitation in patients with OA (effect size [ES] =.31; 95% confidence interval [CI],.099-.520), but not in reducing pain (ES =.22; 95% CI, -.247 to.693). This result, however, is based on only 2 studies. SAMe seems to be comparable with NSAIDs (pain: ES =.12; 95% CI, -.029 to.273; functional limitation: ES =.025; 95% CI, -.127 to.176). However, those treated with SAMe were less likely to report adverse effects than those receiving NSAIDs. CONCLUSIONS: SAMe appears to be as effective as NSAIDs in reducing pain and improving functional limitation in patients with OA without the adverse effects often associated with NSAID therapies. SN - 0094-3509 UR - https://www.unboundmedicine.com/medline/citation/12019049/full_citation DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓18]

Related Citations

    More

    Others Viewed